Genmab To Expand Proprietary Pipeline, Closing In On Marketing Its Own Products
Updates Financial Guidance For 2021
Executive Summary
The antibody discovery and development biotech Genmab is preparing to commercialize its own products in the second half of 2021, as revenues continue to grow from partners and licensees.